PALI/ 12/29/2025 · 6:07 AM Piper Sandler Backs Palisade Bio Ahead of Key Crohn’s Data Piper Sandler starts coverage on Palisade Bio with an Overweight rating and a $25 target, citing strong potential for its Crohn’s disease drug PALI-2108.